Hemogenyx Pharmaceuticals Plc enters CAR-T agreement with University of Pennsylvania; stocks surge 13%

  • Aug 11, 2020 BST
  • Team Kalkine
Hemogenyx Pharmaceuticals Plc enters CAR-T agreement with University of Pennsylvania; stocks surge 13%


Hemogenyx Pharmaceuticals Plc (LON: HEMO) has entered into CAR-T agreement with University of Pennsylvania.

  • The company has entered into a Sponsored Research Agreement with an aim to advance the CAR (Chimeric Antigen Receptor) T-cells, known as “HEMO-CAR-T" developed by the company toward clinical trials.
  • The agreement is considered as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukaemia.
  • On 11 August 2020, at the time of writing, GMT 08:05 AM, HEMO shares were trading at GBX 10.13, up by 1.17 points or 13% against the previous day closing price.


The website https://kalkinemedia.com/uk is a service of Kalkine Media Ltd, Company Number 12643132. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform.


With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK